249 related articles for article (PubMed ID: 17713881)
1. [Economic effects of "molecular" medicine].
Riemann JF
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1740. PubMed ID: 17713881
[No Abstract] [Full Text] [Related]
2. [Innovative therapy, early and cost-benefit assessment].
Dierks C
Onkologie; 2012; 35 Suppl 2():7. PubMed ID: 22517064
[No Abstract] [Full Text] [Related]
3. Researching the cost of research.
Wright JR; Levine MN
J Clin Oncol; 2003 Nov; 21(22):4081-2. PubMed ID: 14559890
[No Abstract] [Full Text] [Related]
4. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
5. [Economic evaluation in oncology].
Schöffski O
Med Klin (Munich); 2000 Jun; 95 Suppl 1():14-7. PubMed ID: 10941248
[TBL] [Abstract][Full Text] [Related]
6. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
7. Era of personalized medicine may herald end of soaring cancer costs.
Keogh B
J Natl Cancer Inst; 2012 Jan; 104(1):12-3, 16-7. PubMed ID: 22173586
[No Abstract] [Full Text] [Related]
8. Can treatment costs be tamed?
Malakoff D
Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
[No Abstract] [Full Text] [Related]
9. [Methodology of pharmacoeconomic studies in oncology].
Ballatori E
Recenti Prog Med; 2008 Jan; 99(1):42-7. PubMed ID: 18389873
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation in clinical nephrology: part 2. Applying economic evaluations in clinical nephrology.
Wong G; Howard K; Craig JC
Nephrology (Carlton); 2010 Aug; 15(5):533-9. PubMed ID: 20649872
[TBL] [Abstract][Full Text] [Related]
11. Optional copayments on anti-cancer drugs.
van de Vooren K; Curto A; Garattini L
BMJ; 2013 Jan; 346():f349. PubMed ID: 23347986
[No Abstract] [Full Text] [Related]
12. Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis.
Tirelli U; Berretta M; Bearz A; Carbone A
Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1355-6. PubMed ID: 22195374
[No Abstract] [Full Text] [Related]
13. News from "the real world": cost-effectiveness in palliative care.
Support Care Cancer; 1994 Jul; 2(4):211-2. PubMed ID: 7522105
[No Abstract] [Full Text] [Related]
14. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
15. Why managed care should provide supportive therapies for cancer patients.
Rubenstein SA
Manag Care; 1995 Aug; 4(8):37-9. PubMed ID: 10145013
[No Abstract] [Full Text] [Related]
16. "To the heart of the matter...".
Kamen BA; Drachtman R
Pediatr Hematol Oncol; 2000; 17(1):5-7. PubMed ID: 10689709
[No Abstract] [Full Text] [Related]
17. New "managed access" process for Cancer Drugs Fund to go ahead, NHS England confirms.
Mayor S
BMJ; 2016 Feb; 352():i1208. PubMed ID: 26926879
[No Abstract] [Full Text] [Related]
18. Does evidence-based medicine really reduce costs?
Kolodziej MA
Oncology (Williston Park); 2011 Mar; 25(3):214, 218. PubMed ID: 21548463
[TBL] [Abstract][Full Text] [Related]
19. Inequalities in oncology care: Economic consequences of high cost drugs.
Niezen MG; Stolk EA; Steenhoek A; Uyl-De Groot CA
Eur J Cancer; 2006 Nov; 42(17):2887-92. PubMed ID: 16979891
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics in the era of individualized medicine.
Waldman SA; Terzic A
Clin Pharmacol Ther; 2008 Aug; 84(2):179-82. PubMed ID: 18679176
[No Abstract] [Full Text] [Related]
[Next] [New Search]
